** charts before earnings **
** charts after earnings **
Sangamo BioSci beats by $0.11, beats on revs; guides FY17 :
- Reports Q4 (Dec) loss of $0.14 per share, $0.11 better than the Capital IQ Consensus of ($0.25); revenues fell 2.2% year/year to $8.9 mln vs the $3.9 mln Capital IQ Consensus.
- Co issues guidance for FY17, sees FY17 revs of $14-19 mln vs. $20.44 mln Capital IQ Consensus Estimate.
- Sangamo expects that its cash, cash equivalents and marketable securities will be at least $60 million at the end of 2017, sufficient to last well beyond anticipated timing of data announcements from the four clinical trials of the Company's four lead development programs. This anticipated cash balance is inclusive of research funding from existing collaborators but exclusive of funds arising from any additional new collaborations or partnerships or other sources of capital.
- Priorities and Expectations for 2017:
- Enroll Phase 1/2 clinical trials for Sangamo's four lead programs with data expected in late 2017 or early 2018, once the Company has gathered sufficient quantity of information from each study to understand clinical relevance:
- Extend technological advantages (efficiency, precision, specificity) of ZFN platform for genome editing Advance novel delivery methods, including lipid nanoparticles, toward clinical development
- Work closely with collaborator Bioverativ on the development of ZFN-mediated genome editing programs for two rare blood disorders, sickle cell disease and beta thalassemia
No comments:
Post a Comment